Cargando…

Discovery of GPR183 Agonists Based on an Antagonist Scaffold

The G protein‐coupled receptor GPR183/EBI2, which is activated by oxysterols, is a therapeutic target for inflammatory and metabolic diseases where both antagonists and agonists are of potential interest. Using the piperazine diamide core of the known GPR183 antagonist (E)‐3‐(4‐bromophenyl)‐1‐(4‐(4‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kjær, Viktoria M. S., Ieremias, Loukas, Daugvilaite, Viktorija, Lückmann, Michael, Frimurer, Thomas M., Ulven, Trond, Rosenkilde, Mette M., Våbenø, Jon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518411/ https://www.ncbi.nlm.nih.gov/pubmed/34270165 http://dx.doi.org/10.1002/cmdc.202100301

Ejemplares similares

Ligand entry pathways control the chemical space recognized by GPR183
por: Kjær, Viktoria Madeline Skovgaard, et al.
Publicado: (2023)

GPR183 Is Dispensable for B1 Cell Accumulation and Function, but Affects B2 Cell Abundance, in the Omentum and Peritoneal Cavity
por: Barington, Line, et al.
Publicado: (2022)

Molecular Characterization of Oxysterol Binding to the Epstein-Barr Virus-induced Gene 2 (GPR183)
por: Benned-Jensen, Tau, et al.
Publicado: (2012)

Receptor structure-based discovery of non-metabolite agonists for the succinate receptor GPR91
por: Trauelsen, Mette, et al.
Publicado: (2017)

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization
por: Jørgensen, Astrid S., et al.
Publicado: (2021)

Structure-Activity Investigations and Optimisations of Non-metabolite Agonists for the Succinate Receptor 1
por: Rexen Ulven, Elisabeth, et al.
Publicado: (2018)

Arrestin‐independent constitutive endocytosis of GPR125/ADGRA3
por: Spiess, Katja, et al.
Publicado: (2019)

Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets
por: Ulven, Trond
Publicado: (2012)

Oxysterol-EBI2 signaling in immune regulation and viral infection
por: Daugvilaite, Viktorija, et al.
Publicado: (2014)

Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1
por: Lückmann, Michael, et al.
Publicado: (2019)

GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection
por: Foo, Cheng Xiang, et al.
Publicado: (2023)

A Blunted GPR183/Oxysterol Axis During Dysglycemia Results in Delayed Recruitment of Macrophages to the Lung During Mycobacterium tuberculosis Infection
por: Ngo, Minh Dao, et al.
Publicado: (2022)

Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines
por: Hjortø, Gertrud M., et al.
Publicado: (2016)

Corrigendum: Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines
por: Hjortø, Gertrud M., et al.
Publicado: (2017)

Biased Signaling of CCL21 and CCL19 Does Not Rely on N-Terminal Differences, but Markedly on the Chemokine Core Domains and Extracellular Loop 2 of CCR7
por: Jørgensen, Astrid S., et al.
Publicado: (2019)

CD4(+)-mediated colitis in mice is independent of the GPR183 and GPR18 pathways
por: Dicker, Martina, et al.
Publicado: (2022)

GPR183 Regulates Interferons, Autophagy, and Bacterial Growth During Mycobacterium tuberculosis Infection and Is Associated With TB Disease Severity
por: Bartlett, Stacey, et al.
Publicado: (2020)

The non-ELR CXC chemokine encoded by human cytomegalovirus UL146 genotype 5 contains a C-terminal β-hairpin and induces neutrophil migration as a selective CXCR2 agonist
por: Berg, Christian, et al.
Publicado: (2022)

The Zinc-Sensing Receptor GPR39 in Physiology and as a Pharmacological Target
por: Laitakari, Anna, et al.
Publicado: (2021)

The Molecular Basis of Ligand Interaction at Free Fatty Acid Receptor 4 (FFA4/GPR120)
por: Hudson, Brian D., et al.
Publicado: (2014)

Selective release of gastrointestinal hormones induced by an orally active GPR39 agonist
por: Grunddal, Kaare V., et al.
Publicado: (2021)

The GPR120 agonist TUG‐891 promotes metabolic health by stimulating mitochondrial respiration in brown fat
por: Schilperoort, Maaike, et al.
Publicado: (2018)

Identification of a novel scaffold for a small molecule GPR139 receptor agonist
por: Nøhr, Anne Cathrine, et al.
Publicado: (2019)

Polyunsaturated fatty acid receptors, GPR40 and GPR120, are expressed in the hypothalamus and control energy homeostasis and inflammation
por: Dragano, Nathalia R. V., et al.
Publicado: (2017)

Rapid GPR183-mediated recruitment of eosinophils to the lung after Mycobacterium tuberculosis infection
por: Bohrer, Andrea C., et al.
Publicado: (2022)

Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands
por: Sergeev, Eugenia, et al.
Publicado: (2016)

3-OBA Is Not an Antagonist of GPR81
por: Mohammad Nezhady, Mohammad Ali, et al.
Publicado: (2022)

Development of Relaxin-3 Agonists and Antagonists Based on Grafted Disulfide-Stabilized Scaffolds
por: Lee, Han Siean, et al.
Publicado: (2020)

Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists
por: Watterson, Kenneth R., et al.
Publicado: (2014)

In vivo Effects of a GPR30 Antagonist
por: Dennis, Megan K., et al.
Publicado: (2009)

Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes
por: Christiansen, Elisabeth, et al.
Publicado: (2013)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
por: Tosh, Dilip K., et al.
Publicado: (2018)

GPR40 (FFAR1) – Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo
por: Hauge, Maria, et al.
Publicado: (2014)

Multiple tyrosine metabolites are GPR35 agonists
por: Deng, Huayun, et al.
Publicado: (2012)

Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
por: Sparre‐Ulrich, A H, et al.
Publicado: (2015)

Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes
por: Mandøe, Mette Johannsen, et al.
Publicado: (2018)

Novel Potent and Selective Agonists of the GPR55 Receptor Based on the 3-Benzylquinolin-2(1H)-One Scaffold
por: Ceni, Costanza, et al.
Publicado: (2022)

Discovery of Potent Tetrazole Free Fatty Acid Receptor 2 Antagonists
por: Valentini, Alice, et al.
Publicado: (2023)

Activation of GPR40 induces hypothalamic neurogenesis through p38- and BDNF-dependent mechanisms
por: Engel, Daiane F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rbd6bad6upjgdft2r4c6h6tggi